Literature DB >> 16319042

Inter-operator variation in ELISPOT analysis of measles virus-specific IFN-gamma-secreting T cells.

J E Ryan1, I G Ovsyannikova, N Dhiman, N A Pinsky, R A Vierkant, R M Jacobson, G A Poland.   

Abstract

The ELISPOT assay is a highly sensitive technique used for the detection of individual cytokine releasing cells. We have developed an IFN-gamma ELISPOT assay utilizing unfractionated frozen peripheral blood mononuclear cells (PBMC) to quantify the frequency of measles virus (MV)-specific IFN-gamma-secreting T cells in 117 healthy children who had been previously immunized with two doses of the measles-mumps-rubella vaccine. We have also estimated the variability associated with the quantification of ELISPOT plates and compared the number of MV-specific IFN-gamma-secreting T cells for each subject as determined by two different operators of an ELISPOT reader. The median frequency of MV-specific IFN-gamma-producing memory T cells detected by this assay was 0.005 % and 0.01 % as determined by an in-house and commercial operator, respectively. Although we found a significant correlation (r = 0.83, p<0.0001) between the number of spots counted by the commercial and in-house operators of an ELISPOT reader, the median number of spots counted by the commercial operator was twice the number of spots counted by an in-house operator (p<0.001). This demonstrates the importance of using a common ELISPOT reader and operator, among other parameters, to quantify the number of spots when a large volume of plates are being scanned and analyzed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16319042     DOI: 10.1080/00365510500348252

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  17 in total

1.  Genome-wide genetic associations with IFNγ response to smallpox vaccine.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Iana H Haralambieva; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Hum Genet       Date:  2012-06-03       Impact factor: 4.132

2.  Correlations between vaccinia-specific immune responses within a cohort of armed forces members.

Authors:  Benjamin J Umlauf; Inna G Ovsyannikova; Iana H Haralambieva; Richard B Kennedy; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Viral Immunol       Date:  2011-09-29       Impact factor: 2.257

3.  Differential cellular immune responses to wild-type and attenuated edmonston tag measles virus strains are primarily defined by the viral phosphoprotein gene.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Neelam Dhiman; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  J Med Virol       Date:  2010-11       Impact factor: 2.327

Review 4.  Therapeutic cancer vaccines: the latest advancement in targeted therapy.

Authors:  Marijo Bilusic; Ravi A Madan
Journal:  Am J Ther       Date:  2012-11       Impact factor: 2.688

5.  Multigenic control of measles vaccine immunity mediated by polymorphisms in measles receptor, innate pathway, and cytokine genes.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Iana H Haralambieva; Megan M O'Byrne; Robert M Jacobson; V Shane Pankratz; Gregory A Poland
Journal:  Vaccine       Date:  2012-01-20       Impact factor: 3.641

Review 6.  The current and emerging role of immunotherapy in prostate cancer.

Authors:  Ravi A Madan; James L Gulley
Journal:  Clin Genitourin Cancer       Date:  2010-12-01       Impact factor: 2.872

7.  Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2011-08-27       Impact factor: 3.641

Review 8.  Immunotherapy in prostate cancer: emerging strategies against a formidable foe.

Authors:  Marijo Bilusic; Christopher Heery; Ravi A Madan
Journal:  Vaccine       Date:  2011-07-07       Impact factor: 3.641

9.  Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer.

Authors:  Ravi A Madan; Thomas Schwaab; James L Gulley
Journal:  J Natl Compr Canc Netw       Date:  2012-12-01       Impact factor: 11.908

10.  2'-5'-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine.

Authors:  Iana H Haralambieva; Neelam Dhiman; Inna G Ovsyannikova; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Hum Immunol       Date:  2010-01-31       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.